Synthesis and characterization of a highly potent and selective isotopically labeled retinoic acid receptor ligand, ALRT1550

Journal of Organic Chemistry

Volumn 63, Issue 3, 1998, Pages 543-550

  Bennani, Youssef L ^a,b   Marron, Kristin S ^a   Mais, Dale E ^a   Flatten, Karen ^a   Nadzan, Alex M ^a,c   Boehm, Marcus F ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Chugai Biopharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 (3,5 DI TERT BUTYLPHENYL) 3 METHYL 2,4,6 OCTATRIENOIC ACID; ALITRETINOIN; RETINOIC ACID; RETINOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING COMPETITION; CONCENTRATION RESPONSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING; LIGAND BINDING;

EID: 0032489022     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo971409i     Document Type: Article

References (32)

1. Mangelsdorf, D. J.; Umesono, K.; Evans, R. M. The Retinoids; Academic Press: Orlando, FL, 1994; pp 319-349.
2. Leid, M.; Kastner, P.; Chambon, P. Trends Biochem. Sci. 1992, 17, 427-433.
3. Chemistry and Biology of Synthetic Retinoids; Dawson, M. I., Okamura, W. H., Eds.; CRC Press: Boca Raton, FL, 1990.
4. The Retinoids. Biology, Chemistry and Medicine, 2nd ed.; Sporn, M. B., Roberts, A. B., Goodman, D. S., Eds.; Raven Press: New York, 1994.
5. Biro, D. E.; Shalita, A. R. Skin Pharm. 1993, 6 (Suppl. 1), 24-34.
6. Shahidallah, M.; Tham, S. N.; Goh, C. L. Int. J. Dermatol. 1994, 33, 60-63.
7. Heyman, R. A.; Mangelsdorf, D. J.; Dyck, J. A.; Stein, R. B.; Eichele, G.; Evans, R. M.; Thaller, C. Cell 1992, 68, 397-406.
8. Boehm, M. F.; McClurg, M. M.; Pathirana, C.; Mangelsdorf, D.; White, S. K.; Hebert, J.; Winn, D.; Goldman, M. E.; Heyman, R. A. J. Med. Chem. 1994, 37, 408-414.
9. Bennani, Y. L.; Boehm, M. F. J. Org. Chem. 1995, 60, 1195-1200.
10. Orfanos, C. E.; Ehlert, R.; Gollnick, H. Drugs 1987, 34, 459-503.
11. Smith, M. A.; Parkinson, D. R.; Cheson, B. D.; Friedman, M. A. J. Clin. Oncol. 1992, 10, 839-864.
12. Vokes, E. E.; Weichselbaum, R. R.; Lippman, S. M.; Hong, W. K. N. Engl. J. Med. 1993, 328, 184-194.
13. Zhang, L.; Nadzan, A. M; Heyman, R. A; Love, D; Mais, D. E; Croston, G; Lamph, W. L; Boehm, M. F. J. Med. Chem. 1996, 39, 2659-2663.
14. Mangelsdorf, D. J; Ong, E. S; Dyck, J. A; Evans, R. M. Nature 1990, 345, 224-229.
15. Berger, T. S; Parandoosh, Z; Perry, B. W; Stein, R. B. J. Steroid Biochem. Mol. Biol. 1992, 41, 733-738.
16. Umesono, K; Giguere, V; Glass, C. K; Rosenfeld, M. G; Evans, R. M. Nature 1988, 336, 262-265.
17. Blaner, W. S.; Olson, J. A. In The Retinoids: Biology, Chemistry and Medicine, 2nd ed.; Sporn, M. B., Roberts A. B., Goodman, D. S., Eds.; Raven Press: New York, 1994; p 229.
18. Nahm, S.; Weinreb, S. M. Tetrahedron Lett. 1981, 22, 3815-3818.
19. Shirley, M. A; Bennani, Y. L; Boehm, M. F; Breau, A. P; Pathirana, C; Ulm, E. H. Drug Metab. Dispos. 1996, 24, 293-302.
20. McDougal, P. G.; Rico, J. G.; Oh, Y. I.; Condon, B. D. J. Org. Chem. 1986, 51, 3388-3390.
21. Martin, S. F.; Phillips, G. W.; Puckette, T. A.; Colapret, J. A. J. Am. Chem. Soc. 1980, 102, 5866-5872.
22. Davidson, S. K.; Phillips, G. W.; Martin, S. F. Org. Synth. 1987, 65, 119-134.
23. Kim, S.; Oh, C.-H.; Ko, J. S.; Anh, K.-H.; Kim, Y.-J. J. Org. Chem. 1985, 50, 1927-1932.
24. 3SnH conditions (see Parnes, H.; Pease, J. J. Org. Chem. 1979, 44, 151-152); reduction of the tosylate derived from 26 (TsCl, Py neat, 84%) using lithium triethylborohydride according to Binkley, R. W. J. Org. Chem. 1985, 50, 5646-5649. For LAH reduction of neopentylic tosylates, see: Collins, D. J.; Jacobs, H. A. Aust. J. Chem. 1986, 39, 2095-2110.
25. 3SnH conditions (see Parnes, H.; Pease, J. J. Org. Chem. 1979, 44, 151-152); reduction of the tosylate derived from 26 (TsCl, Py neat, 84%) using lithium triethylborohydride according to Binkley, R. W. J. Org. Chem. 1985, 50, 5646-5649. For LAH reduction of neopentylic tosylates, see: Collins, D. J.; Jacobs, H. A. Aust. J. Chem. 1986, 39, 2095-2110.
26. 3SnH conditions (see Parnes, H.; Pease, J. J. Org. Chem. 1979, 44, 151-152); reduction of the tosylate derived from 26 (TsCl, Py neat, 84%) using lithium triethylborohydride according to Binkley, R. W. J. Org. Chem. 1985, 50, 5646-5649. For LAH reduction of neopentylic tosylates, see: Collins, D. J.; Jacobs, H. A. Aust. J. Chem. 1986, 39, 2095-2110.
27. 3SnH conditions (see Parnes, H.; Pease, J. J. Org. Chem. 1979, 44, 151-152); reduction of the tosylate derived from 26 (TsCl, Py neat, 84%) using lithium triethylborohydride according to Binkley, R. W. J. Org. Chem. 1985, 50, 5646-5649. For LAH reduction of neopentylic tosylates, see: Collins, D. J.; Jacobs, H. A. Aust. J. Chem. 1986, 39, 2095-2110.
28. 3SnH conditions (see Parnes, H.; Pease, J. J. Org. Chem. 1979, 44, 151-152); reduction of the tosylate derived from 26 (TsCl, Py neat, 84%) using lithium triethylborohydride according to Binkley, R. W. J. Org. Chem. 1985, 50, 5646-5649. For LAH reduction of neopentylic tosylates, see: Collins, D. J.; Jacobs, H. A. Aust. J. Chem. 1986, 39, 2095-2110.
29. For Zn/AcOH reduction of neopentylic iodides, see: Ito, M.; Kibayashi, C. Synthesis 1993, 137-140.
30. 3 reduction of a steroidal neopentylic hydrazone, see: Schenk, V. G.; Albrecht, H. P.; Lietz, H. Drugs Res. 1978, 28, 518.
31. Leoliger, P.; Bollag, W.; Mayer, H. Eur. J. Med. Chem. 1980, 15, 9-15.
32. Cheng, Y.-C.; Prusoff, W. F. Biochem. Pharmacol. 1973, 22, 3099-3108.